期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

分子靶向抗癌药物埃洛替尼的研究进展 被引量：1

下载PDF
导出
摘要 由于结构生物学的发展,使药物的开发过程大大加速,其中激酶结构生物学的作用又远远大于其它类型的靶标。酪氨酸激酶是蛋白激酶家族中主要成员之一,其作为开发抗癌药物的靶标日益受到重视。埃洛替尼(Erlotin-ib,Tarcava,OSI774)是表皮生长因子受体(EGFR)酪氨酸激酶可逆性抑制剂,在离体实验均显示埃洛替尼对非小细胞肺癌(NSCLC)和胰腺癌有不同程度的抑制作用。该靶向抗癌药的主要特点是安全性和耐受性好,毒副反应轻。本文就埃洛替尼对NSCLC和胰腺癌等恶性肿瘤靶向治疗的最新研究进展进行综述。
作者 刘小玲 李慧林
机构地区 杭州师范学院基础医学部药理学教研室
出处 《杭州师范学院学报（医学版）》 CAS 2006年第5期336-340,共5页 Journal of Hangzhou Teachers College :Medical Edition
关键词 恶性肿瘤 靶向抗癌药 埃洛替尼
分类号 R979.1 [医药卫生—药品]
  • 相关文献

参考文献17

  • 1陈喆,戴媛媛,汤致强.小分子EGFR酪氨酸激酶抑制剂盐酸埃罗替尼[J].中国新药杂志,2005,14(10):1227-1229. 被引量：19
  • 2王蔚.抗肿瘤药Erlotinib[J].药学进展,2005,29(4):190-191. 被引量：1
  • 3[3]Soler RP,Dai Q,Ling YH,et al.Molecular mechanisms of sensitivity and resistance to the HERI/EGFR-tyroinse kinase inhibitor erlotinib(TarcevaTM)[J].Lung Cancer,2003,4 1(Suppl 3):S72.
  • 4[4]Fukuoka M.Epidermal growth factor receptor tyrosine kinase inhibitors:single agent Therapy[J].Lung Cancer,2003,41 (Suppl 2):S38
  • 5[5]Rudin CM,Kozloff M,Edelman M J,et al.Bcl-2 as a target in lung cancer[J].Lung Cancer,2003,41 (Suppl 2):S80.
  • 6[6]Sander A,Natale R,Blajman C,et al.A phase Ⅱ efficacy study of Brostallicin,a novel Minor GrooveBinder (MGB),in patients with platinum refractory or resistant non-small cell lung cancer(NSCLC)[J].Lung Cancer,2003,41 (Suppl 2):S118.
  • 7[7]Soler RP.Chachoua A,Huberman M,et al.Final results from a phase-Ⅱstudy of erlotinib (TarcevaTM) monotherapy in patients with advanced non-small cell lung cancer following failure of platinum-based chemotherapy[J].Lung Cancer,2003,41 (Suppl 3):S246-S247.
  • 8[9]Senzer NN,Soulieres D,Siu L,et al.Phase 2 evaluation of OSI-774,a potent oral antagonist of the EGFR-TK in patients with advanced squamous cell carcinoma of the head and neck[abstract][J].Proc Am Soc Clin Oncol,2001,20:2a[Abstract 6].
  • 9[10]Perez-Soler R,Chachoua A,Hammond LA,et al.Determinants of tumor response and survival with erlotinib in patients with non-small cell lung cancer[J].J Clin Oncol,2004,22 (16):3238-3247.
  • 10[11]Finkler N,Cordon A.Phase 2 evaluation of OSI-774,a potent antagonist of the EGFR-TK in patients with advanced ovarian carcinoma[J].Proc Am Soc Clin Oncol,2001,20:208a.

二级参考文献19

  • 1Hidalgo M, Siu LL. Phase Ⅰ and Pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies[J]. J Clin Oncol, 2001,19(13):3267 - 3279.
  • 2Klapper LN, Kirschbaum MH, Sela M, et al. Biochemical and clinical implications of the ErbB/HER signaling network of growth factor receptors [ J ]. Adv Cancer Res, 2000,77: 25 - 79.
  • 3Mendrola JM, Berger MB, King MC, et al. The single transmenmbrane domains of ErbB receptors self-associate in cell membranes[J]. J Biol Chem, 2002,277(7) :4704 - 4712.
  • 4Moyer JD, Barbacci EG, Iwata KK, et al. Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase [ J ]. Cancer Res, 1997, 57 ( 21 ):4838 - 4848.
  • 5Pollack VA, Savage DM, Baker DA, et al. Inhibition of epidermal growth factor receptor-associated tyrosine phosphorylation in human carcinoma with OSI-774: Dynamics of receptor inhibition in situ and antitumor effects in athymic mice[J]. J Pharmcol Exp Ther, 1999,291(2) :739 - 748.
  • 6Senzer NN, Soulieres D, Siu L, et al. Phase 2 evaluation of OSI-774,a potent oral antagonist of the EGFR-TK in patients with advanced squamous cell carcinoma of the head and neck [ abstract ] [ J ]. Proc Am Soc Clin Oncol, 2001,20: 2a [ Abstract 6 ].
  • 7Perez-Soler R, Chachoua A, Hammond LA, et al. Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer[ J]. J Clin Oncol, 2004,22(16): 3238 - 3247.
  • 8Garland L, Rankin C . Molecular correlates of the EGFR signaling pathway in association with SWOGS0218: A phase Ⅱ study of oral EGFR tyrosine kinase inhibitor OSI-774 (NSC-718781) in patients with malignant pleural mesothelioma (MPM)[ J ]. Proc Am Soc Clin Oncol, 2004,22 ( 14S ): Abstract3007.
  • 9Finkler N, Gordon A. Phase 2 evaluation of OSI-774, a potent antagonist of the EGFR-TK in patients with advanced ovarian carcinoma[J]. Proc Am Soc Clin Oncol, 2001, 20 : 208a .
  • 10Oza AM,Townsley CA. Phase Ⅱ study of erlotinib (OSI-774) in patients with metastatic colorectal [ J ]. Proc Am Soc Clin Oncol,2003,22: Abstract785.

共引文献18

同被引文献6

引证文献1

杭州师范学院学报（医学版）
2006年 第5期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部